Records
4 records where Olivier Dussopt is listed as a sponsor, author, or other actor. Search with topics and years
Question· Question écrite2895open
France · National Assembly
Mr. Olivier Dussopt draws the attention of the Minister of Solidarity and Health to the arbitration regulation governing the prices of private dentists, published in the Official Journal of March 29, 2017. This arbitration regulation provides for a four-year cap on prosthetic prices, counterbalanced by a meager increase in conservative care. Even more, a safeguard clause limits oral and dental expenses to 6.8 billion euros in 2018, while they had exceeded 7 billion euros in 2015. In fact, this decision has plunged the profession into suspense since the prices and ceilings imposed weaken the economic balance of private dental practices, and, consequently, the network in the territories, even though the Government has made the fight against medical deserts a priority. Even more, practitioners wishing to offer treatments in accordance with current scientific data will have to exercise outside the conventional framework, which does not allow their management. As a result, quality care will be reserved for wealthy people who can bear the cost alone. The most modest will have to be content with the most basic techniques, or turn to care structures backed by the 1901 law, the abuses of which were illustrated by the Dentexia health scandal. possible. In a desire for dialogue, the Government suspended the application of the pricing of the arbitration settlement and convened new conventional negotiations. This must be an opportunity to renovate a model which has not been reformed for thirty years and which corresponds to outdated dentistry. Indeed, the challenge is to adapt the regulatory framework to innovative practices favoring the preservation of the tooth rather than its mutilation, for the greater benefit of patients. It is now crucial to emphasize prevention; the solutions exist and professionals are eager to implement them. In this sense, it is appropriate to go beyond the framework of the current conventional negotiations and to adopt a new ambitious roadmap, integrating a real overhaul of French dentistry. This is why he asks him to please clarify his intentions in this matter.
Question· Question écrite2214open
France · National Assembly
Mr. Olivier Dussopt wishes to draw the attention of the Minister of the Economy and Finance to the consequences for professionals in the stationery and office supplies sector of the reduction in payment deadlines imposed by the law on the modernization of the economy of August 4, 2008. Since its implementation, professionals in the sector have suffered from a growing imbalance between shorter payment deadlines to suppliers and customer payment deadlines which remain unchanged during the back-to-school period. In addition, asking distributors with little cash flow to pay for their back-to-school orders in a relatively short time leads them to have them delivered as late as possible before the start of this period and then request restockings until the beginning of September. Also, as it is impossible for producers to manufacture in just a few months, in the spring, everything that will be sold during the back-to-school period, this forces them to store their production since September of the previous year, with a storage peak in May which necessarily involves storage outside their depot for those like notebook or binder manufacturers who have bulky products. Outside of cost of storage, producers also have to face a shortage of available delivery people during the summer period. There are today exemptions in the agricultural equipment sector, for the sale of seasonal sporting goods, as well as for the toy trade in order to respond to the difficulties of the Christmas period. This is why he would like to know the Government's position and the measures it intends to take concerning an exemption for resellers of school supplies during the back-to-school period.
Question· Question écrite140answered
France · National Assembly
Mr. Olivier Dussopt draws the attention of the Minister of Agriculture and Food to fraud concerning the exact origin of royal jelly. Until the 1970s, the production of royal jelly constituted a diversification with high added value for many French beekeepers, and for some of them the main production of their farm. Since then, royal jelly from abroad has overwhelmed the French market. This production, often coming from Asia, is most of the time sold without indication of origin and is therefore presented to the consumer as a French product. This situation created such unfair competition that French beekeepers had to abandon this production. While France consumes 350 tonnes of royal jelly per year, including 40 tonnes of fresh jelly, French beekeepers only market 2 tonnes per year. In addition, French beekeepers are confronted in this market with misleading statements concerning the origin of the product. Indeed, many products on sale are presented as French or in a manner suggesting so even though they are an imported product. Many consumers buy imported royal jelly without knowing it, even though they claim to attach great importance to the origin of the product (see the study “The royal jelly market in France” conducted by FranceAgriMer in 2015). Also, he asks what measures can be taken so that French beekeepers can produce quality royal jelly, without facing foreign competition and so that the exact origin can be appreciated by consumers.
Question· Question écrite400open
France · National Assembly · 7 January 2017
Mr. Olivier Dussopt draws the attention of the Minister of Solidarity and Health to the non-inscription on the so-called “additional” list of certain innovative medications used in the treatment of multiple myeloma. The latter is a malignant disease of the bone marrow that affects nearly 5,000 new people each year. Today, the number of people suffering from multiple myeloma is estimated at 30,000 people in France. In In terms of treatment, a major breakthrough was obtained in 2015 with the delivery of marketing authorization for five new drugs at the initiative of the European Medicines Agency. However, some of these innovative medicines, which meet all the conditions to be included on the “additional list”, such as carfilzomib, do not benefit from the exceptional financing system allowing hospitals to offer these innovative and expensive treatments to patients as quickly as possible by having their financing directly covered by health insurance. Also, he would like to know the reasons for these non-registrations and if the Government plans to put an end to them.